Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard Sells 2,000 Shares

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the business’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $8.67, for a total value of $17,340.00. Following the sale, the chief executive officer now owns 14,619,350 shares of the company’s stock, valued at approximately $126,749,764.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Thomas Sandgaard also recently made the following trade(s):

• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.82, for a total value of $17,640.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.63, for a total value of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.92, for a total transaction of $17,840.00.

Zynex Price Performance

Zynex stock opened at $9.21 on Thursday. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. The firm has a market capitalization of $293.30 million, a P/E ratio of 61.40 and a beta of 0.53. The business has a 50-day moving average of $8.14 and a 200-day moving average of $9.00. Zynex, Inc. has a 1 year low of $7.15 and a 1 year high of $13.77.

Zynex (NASDAQ:ZYXI) last issued its quarterly earnings data on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The firm had revenue of $49.97 million during the quarter, compared to analysts’ expectations of $50.83 million. During the same quarter in the previous year, the company earned $0.10 earnings per share. The business’s revenue for the quarter was up .1% on a year-over-year basis. On average, equities analysts anticipate that Zynex, Inc. will post 0.2 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ZYXI shares. Royal Bank of Canada cut their price objective on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. HC Wainwright increased their price target on Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, October 25th.

Institutional Trading of Zynex

A number of large investors have recently made changes to their positions in ZYXI. Renaissance Technologies LLC lifted its holdings in Zynex by 68.7% during the second quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock worth $1,769,000 after acquiring an additional 77,300 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Zynex by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 1,187,089 shares of the company’s stock valued at $14,684,000 after purchasing an additional 6,097 shares in the last quarter. Millennium Management LLC grew its position in shares of Zynex by 66.5% in the 2nd quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock valued at $2,769,000 after purchasing an additional 118,615 shares during the period. Quest Partners LLC increased its stake in Zynex by 646.7% during the 2nd quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock worth $120,000 after purchasing an additional 11,195 shares in the last quarter. Finally, LSV Asset Management raised its holdings in Zynex by 45.1% during the 1st quarter. LSV Asset Management now owns 108,935 shares of the company’s stock worth $1,348,000 after buying an additional 33,840 shares during the period. Institutional investors own 29.68% of the company’s stock.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.